Proneurotensin predicts CVD in elderly population
Proneurotensin is an independent predictor of cardiovascular disease (CVD) development in both men and women in the elderly population, but it only predicts diabetes in women, according to a study.
A total of 456 first CVD events and 222 incident cases of diabetes occurred in the study. For every 1 standard deviation (SD) increase in proneurotensin, the hazard ratio (HR) was 1.10 (95 percent CI, 1.01–1.21; p=0.037), and the above vs below median HR was 1.27 (1.06–1.54; p=0.011), with similar effect sizes in both genders.
No significant association was observed between proneurotensin and incident diabetes in the entire population (p=0.52) or among men (p=0.52). However, proneurotensin predicted diabetes incidence in women, with a per 1 SD increment HR of 1.28 (1.30–1.59; p=0.025) and an above vs below median HR of 1.41 (1.10–1.80; p=0.007).
Fasting proneurotensin measurement was performed in plasma obtained from 4,804 participants (mean age 69 years) of the Malmo Preventive Project. Participants were followed up for development of CVD and diabetes for 5.4 years.
Multivariate adjusted Cox proportional hazard models were used to relate the proneurotensin to the risk of incident CVD and diabetes in all subjects and in gender-stratified analyses.
“The gut hormone neurotensin promotes fat absorption, diet-induced weight gain and liver steatosis. Its stable precursor-hormone fragment ‘proneurotensin’ predicts cardiometabolic disease in middle-aged populations, especially in women,” the investigators noted.
In a previous study, Melander and colleagues found a significant association between fasting proneurotensin and the development of diabetes, CVD, breast cancer, and total and CV mortality. [JAMA 2012;308:1469-1475]